Skip to search formSkip to main contentSkip to account menu

telatinib

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Hypertension is a common side-effect in cancer patients treated with inhibitors of VEGF/VEGFR-2 signaling and may represent a… 
Review
2014
Review
2014
The phenomenon of multidrug resistance (MDR) has attenuated the efficacy of anticancer drugs and the possibility of successful… 
2012
2012
Abstract Literature data on the clinical pharmacokinetics of various VEGFR-2 inhibitors along with in vitro potency data were… 
2011
2011
BACKGROUND Blocking both receptor and ligand of the vascular endothelial growth factor (receptor) VEGF(R) pathway might be… 
2011
2011
4122 Background: Angiogenesis is essential for tumor growth and plays an important role in metastasis in gastrointestinal (GI… 
2011
2011
113 Background: The soluble form of the VEGFR2 receptor (sVEGFR2) neutralizes circulating VEGF, and functions as a negative… 
2010
2010
e14575 Background: Telatinib (T) is a potent small molecule oral tyrosine kinase inhibitor selectively targeting the VEGF and… 
2009
2009
PURPOSE Telatinib (BAY 57-9352) is an orally available tyrosine kinase inhibitor of vascular endothelial growth factor receptor… 
2009
2009
SummaryPurpose Telatinib is an orally active small-molecule tyrosine kinase inhibitor of kinase insert domain receptor (KDR… 
2008
2008
2530 Background: Telatinib is an orally available, small molecule tyrosine kinase domain inhibitor of the VEGFR-2, VEGFR-3, PDGFR…